MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non–Small-Cell Lung Cancer

Published:2019-04-10 Issue:11 Volume:37 Page:855-857
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Camidge D. Ross¹,Davies Kurtis D.¹

Affiliation:

1. University of Colorado, Anschutz Medical Campus, Aurora, CO

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.19.00033

Reference17 articles.

1. Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

2. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

3. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

4. Ramalingam SS, Cheng Y, Zhou C, et al: Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Proceedings from the 2018 ESMO Congress, Munich, Germany, October 19-23, 2018 (abstr LBA50)

5. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis;Lung Cancer;2024-02

2. Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET;mAbs;2024-01-12

3. Enhancing MET Copy Number Estimation by Factoring in Tumor Purity and Variant Types;Lecture Notes in Computer Science;2024

4. Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches;Cancers;2023-09-14

5. Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC;International Journal of Molecular Sciences;2023-08-23